Company Overview and News
Ford Motor Company (F - Free Report) plans to extend partnership with other carmakers in order to restructure its business and cut costs, per Reuters. The company is in talks with German automaker Volkswagen AG (VLKAY - Free Report) and Mahindra and Mahindra Ltd. based in India to expand alliances and develop products. Ford plans to share manufacturing plant floor capacity as well as develop vehicles with its partners.
VLKAF KMX AZO GPN VLKAY
Good morning. My name is Jamie and I will be your conference operator today. At this time, I would like to welcome everyone to the CarMax fiscal 2019 second quarter earnings conference call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question and answer session. Thank you.
Today’s pre-market shows our major U.S. indexes slightly in the green this morning, ahead of a widely anticipated Fed policy decision on interest rates (hint: they’re going up another 1/4 point) this afternoon. This will be followed by a press conference featuring Fed Chair Jerome Powell today at 2:30pm ET.
Wednesday, September 26, 2018 Today’s pre-market shows our major U.S. indexes slightly in the green this morning, ahead of a widely anticipated Fed policy decision on interest rates (hint: they’re going up another 1/4 point) this afternoon. This will be followed by a press conference featuring Fed Chair Jerome Powell today at 2:30pm ET. These interest rate hikes — of which this will be the third so far in 2018, with a high likelihood of a fourth coming this December — do not historically have much sway on the market.
CarMax (KMX - Free Report) came out with quarterly earnings of $1.24 per share, beating the Zacks Consensus Estimate of $1.22 per share. This compares to earnings of $0.98 per share a year ago. These figures are adjusted for non-recurring items.
Investors in CarMax, Inc. (KMX - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 28, 2018 $75.00 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
CarMax Inc. (KMX - Free Report) has posted earnings per share of $1.24 in the second quarter of fiscal 2019 (ended Aug 31, 2018), up 26.5% from 98 cents in the year-ago quarter. Moreover, earnings surpassed the Zacks Consensus Estimate of $1.22. Net sales and operating revenues in the reported quarter increased 8.6% year over year to $4.77 billion. Further, the figure beat the Zacks Consensus Estimate of $4.
FOXF OSK KMX ALSN CAXPF
Shares of CarMax Inc. KMX, +0.00% surged 1% in premarket trade Wednesday, after the used car retailer reported a fiscal second-quarter profit and sales that rose above expectations, as improved conversion rates offset lower store traffic. Net earnings for the quarter to Aug. 31 increased to $220.9 million, or $1.24 a share, from $181.4 million, or 98 cents a share, in the same period a year ago. The FactSet consensus was for earnings of $1.
Rising demand for used cars has come as a huge relief for dealers who were weighed down by concerns related to their declining prices. Prices of these cars were on the decline due to a number of lease expirations toward the end of 2017. Per a report by the Wall Street Journal, the widening gap between new and used vehicles in recent times is pushing more and more shoppers toward used vehicles. This, in turn, is putting tremendous pressure on new vehicle manufacturers and the situation requires them to extend deeper discounts to remain competitive.
AN KMX PAG SAH
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to KMX / CarMax, Inc. on message board site Silicon Investor.
|CarMax (KMX) - a recent IPO of a Circuit City unit||CarMax (KMX) - a recent IPO of a Circuit City unit||CarMax (KMX) - a recent IPO of a Circuit City unit||KMX: CarMax Group||KMX: CarMax Group||KMX: CarMax Group|
as of ET